These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 19365055

  • 1. Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: the ICE Study.
    Merkies IS, Bril V, Dalakas MC, Deng C, Donofrio P, Hanna K, Hartung HP, Hughes RA, Latov N, van Doorn PA, ICE Study Group.
    Neurology; 2009 Apr 14; 72(15):1337-44. PubMed ID: 19365055
    [Abstract] [Full Text] [Related]

  • 2. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.
    Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, Hartung HP, Latov N, Merkies IS, van Doorn PA, ICE Study Group.
    Lancet Neurol; 2008 Feb 14; 7(2):136-44. PubMed ID: 18178525
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV.
    Bril V, Katzberg H, Donofrio P, Banach M, Dalakas MC, Deng C, Hanna K, Hartung HP, Hughes RA, Latov N, Merkies IS, van Doorn PA, ICE Study Group.
    Muscle Nerve; 2009 Apr 14; 39(4):448-55. PubMed ID: 19260050
    [Abstract] [Full Text] [Related]

  • 5. Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study.
    Merkies IS, Hughes RA, Donofrio P, Bril V, Dalakas MC, Hanna K, Hartung HP, Latov N, van Doorn PA, Deng C, ICE Study Group.
    J Peripher Nerv Syst; 2010 Sep 14; 15(3):208-15. PubMed ID: 21040143
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Electrophysiologic correlations with clinical outcomes in CIDP.
    Bril V, Banach M, Dalakas MC, Deng C, Donofrio P, Hanna K, Hartung HP, Hughes RA, Katzberg H, Latov N, Merkies IS, Van Doorn PA, ICE Study Group.
    Muscle Nerve; 2010 Oct 14; 42(4):492-7. PubMed ID: 20665514
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Impact of fesoterodine on quality of life: pooled data from two randomized trials.
    Kelleher CJ, Tubaro A, Wang JT, Kopp Z.
    BJU Int; 2008 Jul 14; 102(1):56-61. PubMed ID: 18564231
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Levocetirizine improves health-related quality of life and health status in persistent allergic rhinitis.
    Walter Canonica G, Bousquet J, Van Hammée G, Bachert C, Durham SR, Klimek L, Mullol J, Van Cauwenberge PB, XPERT Study Group.
    Respir Med; 2006 Oct 14; 100(10):1706-15. PubMed ID: 16723217
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy.
    Comi G, Roveri L, Swan A, Willison H, Bojar M, Illa I, Karageorgiou C, Nobile-Orazio E, van den Bergh P, Swan T, Hughes R, Aubry J, Baumann N, Hadden R, Lunn M, Knapp M, Léger JM, Bouche P, Mazanec R, Meucci N, van der Meché F, Toyka K, Inflammatory Neuropathy Cause and Treatment Group.
    J Neurol; 2002 Oct 14; 249(10):1370-7. PubMed ID: 12382151
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
    Kress HG, Orońska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T.
    Clin Ther; 2009 Jun 14; 31(6):1177-91. PubMed ID: 19695386
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.